Target intelligence / Profile preview

Endogenous retrovirus group 3 member 1 envelope protein (ERV3-1)

Target
ERV3-1
Molecular classification
Other (endogenous retroviral envelope protein)
01

Overview

Endogenous retrovirus group 3 member 1 envelope protein (ERV3-1) is a protein-coding gene remnant of a human endogenous retrovirus, localized on chromosome 7q11[1][2]. The locus is ancient, expressed in several normal tissues—including placenta, adrenal gland, skin, lung, pituitary, and testis[1][2]. It encodes an Env polyprotein homologous to gammaretroviral envelope proteins, with SU (surface) and TM (transmembrane) components. Unlike active exogenous retroviral Env proteins, ERV3-1 Env lacks fusogenic (membrane-fusing) activity in humans[3]. It retains a putative immunosuppressive domain, and in vitro it can inhibit cell proliferation by modulating cell cycle gene expression[2][3]. Only the 7q11 locus harbors a complete open reading frame; all other ERV3-like paralogs are inactivated. ERV3-1 has been reported overexpressed in some cancers and implicated in rare read-through fusions with ZNF117; however, it is not generally regarded as a therapeutic drug target[1][2][3]. The biological and pathological significance of ERV3-1 remains under investigation, with some evidence for roles in cancer, autoimmunity, and placental biology, but no established interacting small molecules or targeted therapies.

Other names
Endogenous retrovirus group 3 member 1 Env polyproteinERV3ERV3 envelope proteinERV-R envelope proteinHERV-RHERV-R_7q21.2 provirus ancestral Env polyproteinEnvelope polyproteinenvRSUTMSurface proteinTransmembrane proteinH-PLKERVRHERVRendogenous retroviral sequence 3endogenous retrovirus group 3, member 1
02

Biological functions

Possible immunosuppressive activityInhibition of cell growth and cell cycle regulation (via decreased cyclin B1, increased p21 expression in vitro)Potential modulation of host gene expression (ERV3 has been shown to read through into the ZNF117 locus)
03

Disease associations

Cancer (ERV3-1 is overexpressed in colorectal and other cancers)Autoimmunity (implicated, but not validated mechanistically)Other (potential roles in placenta function, but physiological significance is debated)
04

Safety considerations

Not considered a therapeutic target, but overexpression in cancer suggests potential as a biomarkerLoss-of-function variants are present in ~1% of the Caucasian population with no clear association with disease

Beyond the preview

Go deeper on Endogenous retrovirus group 3 member 1 envelope protein (ERV3-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endogenous retrovirus group 3 member 1 envelope protein (ERV3-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call